Bioventus (BVS) Cash & Current Investments (2020 - 2026)
Bioventus filings provide 6 years of Cash & Current Investments readings, the most recent being $51.2 million for Q4 2025.
- On a quarterly basis, Cash & Current Investments rose 23.22% to $51.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $51.2 million, a 23.22% increase, with the full-year FY2025 number at $51.2 million, up 23.22% from a year prior.
- Cash & Current Investments hit $51.2 million in Q4 2025 for Bioventus, up from $42.2 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $140.1 million in Q3 2021 to a low of $22.8 million in Q1 2025.
- Median Cash & Current Investments over the past 5 years was $39.0 million (2022), compared with a mean of $51.2 million.
- Biggest five-year swings in Cash & Current Investments: skyrocketed 80.63% in 2021 and later tumbled 75.75% in 2022.
- Bioventus' Cash & Current Investments stood at $49.2 million in 2021, then plummeted by 38.62% to $30.2 million in 2022, then rose by 22.36% to $37.0 million in 2023, then grew by 12.49% to $41.6 million in 2024, then increased by 23.22% to $51.2 million in 2025.
- The last three reported values for Cash & Current Investments were $51.2 million (Q4 2025), $42.2 million (Q3 2025), and $32.9 million (Q2 2025) per Business Quant data.